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ABSTRACT (word count=350) 
Background: The contemporary prognostic value of the physical examination, beyond 
traditional risk factors including natriuretic peptides (NPs), risk scores, and symptoms, in heart 
failure with reduced ejection fraction (HFrEF) is unknown. We sought to determine the 
association between physical signs of congestion at baseline and during study follow up with 
quality of life (QoL) and clinical outcomes and to assess the treatment effects of 
sacubitril/valsartan on congestion. 
Methods: We analyzed participants from PARADIGM-HF (Prospective Comparison of 
Angiotensin Receptor-Neprilysin Inhibitor With Angiotensin Converting Enzyme Inhibitor to 
Determine Impact on Global Mortality and Morbidity in HF) with an available physical 
examination at baseline. We examined the association of the number of signs of congestion 
(jugular venous distention, edema, rales, and S3) with the primary outcome (cardiovascular death 
or HF hospitalization), its individual components, and all-cause mortality using time-updated, 
multivariable-adjusted Cox regression. We further evaluated whether sacubitril/valsartan reduced 
congestion during follow-up, and whether improvement in congestion is related to changes in 
clinical outcomes and QoL, assessed by Kansas City Cardiomyopathy Questionnaire clinical 
summary scores (KCCQ-OSS).  
Results: Among 8380 participants, 0, 1, 2, and 3+ signs of congestion were present in 70%, 
21%, 7%, and 2%. Patients with baseline congestion were older, more often female, had higher 
Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) risk scores and lower KCCQ-
OSS (p<0.05). After adjusting for baseline NPs, time-updated MAGGIC score, and time-updated 
New York Heart Association class, increasing time-updated congestion was associated with all 
outcomes (p<0.001). Sacubitril/valsartan reduced the risk of the primary outcome irrespective of 
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clinical signs of congestion at baseline (p=0.16 for interaction), and treatment with the drug 
improved congestion to a greater extent than enalapril (p=0.011). Each 1-sign reduction was 
independently associated with a 5.1 (95%CI: 4.7-5.5) point improvement in KCCQ-OSS. 
Change in congestion strongly predicted outcomes even after adjusting for baseline congestion 
(p<0.001). 
Conclusions: In HFrEF, the physical exam continues to provide significant, independent 
prognostic value even beyond symptoms, NPs, and MAGGIC risk score.  Sacubitril/valsartan 
improved congestion to a greater extent than enalapril. Reducing congestion in the outpatient 
setting is independently associated with improved QoL and reduced cardiovascular events, 
including mortality.  
Clinical Trials Registration Information: ClinicalTrials.gov identifier: NCT01035255 
 (https://clinicaltrials.gov/ct2/show/NCT01035255)  
 
Keywords: heart failure with reduced ejection fraction; physical exam; sacubitril/valsartan; 
congestion 
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CLINICAL PERSPECTIVES 
 
What is New? 
• In a contemporary, time-updated analysis of patients with heart failure with reduced 
ejection fraction, the number of physical exam signs was strongly predictive of clinical 
outcomes even after adjusting for several confounding variables including baseline 
natriuretic peptides, time-updated Meta-Analysis Global Group in Chronic Heart Failure 
(MAGGIC) risk score, and time-updated New York Heart Association Class.  
• The effect of sacubitril/valsartan relative to enalapril in reducing cardiovascular outcomes 
was consistent across the baseline physical exam and improved congestion over enalapril.  
• Change in the physical exam strongly related to patient-assessed quality of life and, 
further, was prognostic for future events over baseline physical exam.  
What are the Clinical Implications? 
• Our findings reinforce the significant, ongoing clinical relevance of the physical exam in 
HF, reducing congestion as assessed by serial physical exams (which was independently 
associated with improved quality of life and reduced risk for adverse cardiovascular 
events), and the notion that measuring NPs does not substitute for a comprehensive 
physical exam for risk stratification. 
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NON-STANDARD ABBREVIATIONS AND ACRONYMS 
 
Confidence interval (CI) 
Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment (GUIDE-IT) 
Hazard ratio (HR) 
Heart failure with reduced ejection fraction (HFrEF) 
Jugular venous distention (JVD) 
Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) 
N-terminal pro-B-type natriuretic peptide (NT-proBNP) 
New York Heart Association (NYHA) 
Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With Angiotensin 
Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in HF 
(PARADIGM-HF) 
Studies of Left Ventricular Dysfunction (SOLVD) 
Third heart sound (S3)  
Valsartan Heart Failure Trial (Val-HEFT)   
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INTRODUCTION  
With advancements in biochemical, imaging, and invasive hemodynamic assessments of 
patients with heart failure (HF), there is growing concern regarding the lack of clinician interest 
and expertise in performing the cardiovascular physical examination in the contemporary era.1-3 
An analysis of trainees showed poor proficiency in numerous domains of cardiac auscultation,4 
and the physical examination has been considered by some to be a vanishing art.3 Previous 
studies, however, have demonstrated the value of information provided by the physical 
examination. An analysis of Studies of Left Ventricular Dysfunction (SOLVD) showed that 
jugular venous distention (JVD) and a third heart sound (S3) were independently associated with 
progression of HF.5 Similarly, the Valsartan Heart Failure Trial (Val-HEFT) showed the value of 
the number of physical exam signs in the stratification of risk.6 
Despite these available data, several questions remain regarding the relevance of the 
physical exam in HF. First, with the significant evolution of disease-modifying treatments and 
declining risk for adverse events,7, 8 the clinical and prognostic value of the physical exam in the 
contemporary era is uncertain. Second, the independent and incremental value of the physical 
exam beyond symptoms, validated risk scores, and HF biomarkers (e.g. natriuretic peptides 
(NPs)) is unclear. Third, the relation of changes in the physical exam with changes in quality of 
life and prognosis have not been well characterized. Fourth, previous analyses of the physical 
exam in HF have generally focused on the relationship between baseline exam and outcomes,5, 6, 
9 but since congestion can change significantly within patients throughout their clinical 
trajectory, a time-updated analysis might be more informative. Finally, it is unknown whether 
sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, improves congestion over 
enalapril in HF with reduced ejection fraction (HFrEF).  
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We analyzed the clinical and prognostic significance of signs of congestion in the 
PARADIGM-HF (Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With 
Angiotensin Converting Enzyme Inhibitor to Determine Impact on Global Mortality and 
Morbidity in HF) trial. We subsequently evaluated the influence of sacubitril/valsartan on the 
physical exam, and whether improvements in the physical exam were associated with improved 
quality of life and prognosis in patients with HFrEF treated in the modern era.  
 
METHODS 
PARADIGM-HF study design and objectives 
Study data are confidential and cannot be shared according to the terms of the contracts 
of the study. Therefore, the data, analytic methods, and study materials will not be made 
available to other researchers. The design of PARADIGM-HF has been described in detail 
previously.10 Briefly, HF patients at least 18 years of age with New York Heart Association 
(NYHA) class II, III, or IV functional capacity and left ventricular EF <=40%. Additionally, 
patients were required to have a plasma B-type natriuretic peptide (BNP) level of at least 150 
pg/mL (or an N-terminal pro-BNP [NT-proBNP] level ≥600 pg/mL) or, if they had been 
hospitalized for heart failure within the previous 12 months, a BNP of at least 100 pg/mL (or an 
NT-proBNP ≥400 pg/mL). Patients already taking angiotensin-converting enzyme inhibitors or 
angiotensin receptor blockers were eligible if they were taking a daily dose equivalent to 
enalapril 10 mg and were on stable dose of beta-blocker for a minimum of 4 weeks. Key 
exclusion criteria included symptomatic hypotension, systolic blood pressure <100 mm Hg at 
screening, estimated glomerular filtration rate <30 mL/min 1.73 m2, history of angioedema, or 
potassium >5.2 mmol/L. Eligible patients were entered (in a single blinded fashion) into a run-in 
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phase where they took enalapril 10 mg twice daily for 2 weeks followed by sacubitril/valsartan 
100 mg twice daily initially followed by 200 mg twice daily for a 4- to 6-week period. Patients 
without significant intolerances to either drug were randomized in 1:1 ratio to either enalapril 10 
mg twice daily or sacubitril/valsartan 200 mg twice daily in a double-blinded fashion. The study 
was approved by an institutional review committee and informed consent was obtained.  
 
Physical exam and natriuretic peptide data collection 
The presence of jugular venous distention (JVD), S3 heart sound, rales, and edema were 
assessed throughout the trial, including at screening, randomization, and at each study visit 
follow-up.10 Physical exams were performed by clinically trained study personnel authorized to 
perform physical exams based on local regulations. For our analysis, we considered the 
randomization visit, as opposed to the screening visit, the baseline visit since event adjudication 
began at the time of randomization and quality of life scoring was also performed at this visit. 
Per the study protocol, the presence of JVD and S3 were assessed in a “yes” or “no” format. 
Edema was graded as “absent”, “trace”, “feet and ankles”, “lower legs and thighs”, and 
“sacrum”. Rales were graded as “absent”, “basilar only”, or “>1/3 of lung field”. For the main 
analysis, we dichotomized edema as present if edema was graded at least to the level of the feet 
and ankles, and absent otherwise; rales where similarly dichotomized as ‘present’ (either “basilar 
only” or “>1/3 of lung field) or ‘absent’. We also performed a complementary analysis that 
analyzed signs using the original graded format (for rales and edema). We excluded participants 
with incomplete data on the physical exam (N=19) at the randomization visit.  
After run-in, NT pro-BNP measurements were analyzed in a subpopulation of 
participants: at the time of randomization (n=1044 in the sacubitril/valsartan arm and n=1029 in 
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the enalapril arm), 1 month after randomization (n=995 in the sacubitril/valsartan arm and 
n=1003 in the enalapril arm), and 8 months after randomization (n=915 in the sacubitril/valsartan 
arm and n=903 in the enalapril arm).11 Supplementary Figure 1 provides a diagram of the 
relationship of study visits to physical examinations performed and NP laboratory analysis.  
 
Study outcomes 
The primary outcome of PARADIGM-HF was a composite of death from cardiovascular 
cause or a first hospitalization for HF.12 We also assessed several trial secondary outcomes, 
including the time to death from any cause and the change from baseline to 4 months in the 
Kansas City Cardiomyopathy Questionnaire overall summary score (KCCQ-OSS) (on a scale 
from 0 to 100, with higher scores indicating fewer symptoms and physical limitations associated 
with HF). KCCQ was administered in 38 of the 46 countries, excluding countries without 
validated versions of the instrument.13 Adjudication of all clinical outcomes was carried out in a 
blinded fashion by a clinical-end-points committee according to prespecified criteria. 
 
Statistical analysis 
Baseline characteristics are summarized by the total number of signs (0, 1, 2, and 3-4) 
and by individual signs (edema, rales, S3, and JVD) using mean and standard deviation for 
normally distributed variables and median [25th-75th percentile] if non-normally distributed. 
Categorical variables are presented as counts and percentages. The values of NPs were right-
skewed and therefore required log transformation to approximate a normal distribution for 
analysis as a continuous variable. ANOVA and chi-squared tests were performed, with p-values 
shown for trend using linear regression for continuous, normally distributed variables and the 
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method of Cuzick for non-parametric testing of continuous variables.14 We used chi-squared 
trend tests for categorical variables. 
The association between the number of signs and individual signs with the efficacy 
outcomes was assessed using time-updated crude and multivariable-adjusted Cox regression. We 
analyzed the physical exam as a categorical, time-updated variable since this model yielded the 
lowest Akaike Information Criteria for cardiovascular death relative to models using the baseline 
physical exam or modeling the signs of congestion as a continuous variable. In addition, we 
modeled the physical exam as a time-updated variable since the physical exam can change over 
time, mirroring clinical practice.15 Multivariable models were adjusted for baseline covariates 
including 1) baseline NT-proBNP, 2) baseline NT-proBNP and time-updated Meta-Analysis 
Global Group in Chronic Heart Failure (MAGGIC) risk score, and 3) baseline NT-proBNP, 
time-updated MAGGIC risk score, and time-updated NYHA class. The MAGGIC risk score was 
originally derived from a large analysis of patients enrolled in clinical trials and cohort studies to 
predict mortality.16 We have previously validated its use to predict study outcomes in 
PARADIGM-HF.17 Given the available data collected, we time-updated the following 
components of the MAGGIC risk score: age, systolic blood pressure, body mass index, 
creatinine, NYHA class, and HF first diagnosed >18 months ago, with missing covariates at 
follow-up visits carried forward from the last available. An interaction analysis by time-updated 
obesity (body mass index > 30 kg/m2) as well as body mass index (continuous variable) with 
time-updated signs of congestion was performed since obesity may hinder the clinician’s ability 
to assess congestion and influence NP measurements. In addition, we analyzed signs in a graded 
fashion (as rales and edema were dichotomized for the main analysis), using the absence of the 
individual sign as the referent arm. A sign score was constructed based upon relative weighting 
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of the beta-coefficients for cardiovascular mortality, as similarly done in other studies 
(Supplementary Table 1).16 
Because NT-proBNP is only available at 3 time points (Supplementary Figure 1), we 
provided a subanalysis of participants with complete NT-proBNP values, MAGGIC risk score, 
and NYHA class at these time points. We performed a time-updated analysis at these time points 
for signs of congestion and the primary outcome, adjusting for time-updated NT-proBNP, 
MAGGIC score, and NYHA class.   
Since the physical exam might inform a physician’s decision to hospitalize patients, and 
therefore inflate the relationship between signs of congestion and HF-related outcomes, we 
performed a sensitivity analysis. For the primary endpoint (which includes HF hospitalization) 
and HF hospitalization, we censored participants at the time of hospitalization for those 
hospitalized for HF on the same date as a clinic visit (N=169).  
To assess the treatment effect of sacubitril/valsartan relative to enalapril on congestion, 
we compared the percent of patients with any congestion (versus no congestion) between study 
arms over the course of follow-up using binary repeated measures logistic regression. We next 
determined the relationship between the change in signs of congestion with change in KCCQ-
OSS at the 4-month visit. Post-randomization changes from baseline were compared using linear 
regression, controlling for treatment allocation and baseline physical exam as independent 
variables. We further controlled for clinical covariates that were independently associated with 
change in the number of physical exam signs from baseline to the 4-month visit using backward 
stepwise ordinal logistic regression at a significance level of 0.01. Finally, to determine whether 
reducing the number of signs of congestion was associated with improved prognosis, we 
simultaneously entered both the baseline and change in signs of congestion (during study follow-
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up) into models assessing the relationship with the efficacy outcomes. Analyses were performed 
using STATA version 12, and a two-sided p-value < 0.05 was considered statistically significant. 
 
RESULTS 
Baseline characteristics  
 Of the initial study population of 8399 participants in the Americas, we excluded 19 
participants with incomplete physical exam data at baseline. Table 1 lists the baseline 
characteristics of the study population, stratified by number of signs of congestion at baseline: 
5854 (70%) had no signs, 1783 (21%) had 1 sign, 563 (7%) had 2 signs, and 180 (2%) had 3-4 
signs. By individual signs of congestion: 9.7% had JVD, 14.2% had edema, 9.5% had an S3, and 
7.9% had rales. Overall cohort characteristics were similar to those presented in the main 
analysis.12 Patients with more congestive signs were older, more often female, had more 
advanced NYHA class, had higher MAGGIC risk scores and lower KCCQ-OSS, and more 
frequently had hypertension, diabetes mellitus, and atrial fibrillation, (p<0.05 for all 
comparisons). They were also more likely to take diuretics, less likely to take beta-blockers or 
have devices, and had higher NP levels (p<0.05 for all comparisons).  
Supplementary Table 2 shows clinical characteristics by presence of individual signs of 
congestion (JVD, edema, S3, and rales), demonstrating similar trends as observed in Table 1. 
Likewise, characteristics of participants by change in the physical exam between the baseline and 
4 month visit are shown in Supplementary Table 3. Patients who decongested, for example, had 
shorter duration of HF, higher blood pressure, and higher heart rate. Supplementary Table 4 
shows the frequency of the most common combination of signs of congestion. Among the 30% 
of participants with any congestion, the majority only exhibited one sign of congestion. At least 
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two signs were observed in a minority of all patients in the trial at baseline: 2.0% had edema and 
rales, 1.5% had JVD and edema, and 1.3% had JVD and an S3.  
 
Association of physical exam signs and adverse cardiovascular outcomes during follow-up 
At any point during follow-up, 2980 (36%), 2935 (35%), 1547 (18%), 734 (9%), and 184 
(2%) had a maximum of 0, 1, 2, 3, and 4 signs, respectively. Figure 1 shows incidence rates per 
100 person-years for each of the 4 study outcomes (primary endpoint, HF hospitalization, 
cardiovascular death, and all-cause mortality) by trial randomization arm using time-updated 
analysis. The number of events and person-years per sign category in each randomization arm 
are shown in Supplementary Table 5. Of note, participants can contribute person-years to more 
than one category as they increase or decrease in the number of signs of congestion during their 
clinical trajectory. There was a significant, graded relationship between number of signs of 
congestion and incidence rates for each outcome. A complementary figure is presented as 
Supplementary Figure 2 using baseline, instead of time-updated, signs of congestion.  
Table 2 shows time-updated, crude and multivariable-adjusted hazard ratios (HR) for the 
study outcomes, stratified by signs of congestion, with 0 signs designated as the referent group. 
On univariable analysis, using no signs of congestion as the referent group, increasing number of 
signs was associated with an increased risk for all outcomes. Adjusting for baseline NT-proBNP, 
time-updated MAGGIC risk score, and time-updated NYHA class generally diminished the 
strength of these relationships but remained statistically significant. For example, the HRs for the 
primary endpoint for 1, 2, 3, and 4 signs of congestion (versus 0 signs) were 1.48, 1.74, 2.35, and 
5.96, respectively after these multivariable adjustments (p<0.001 for all sign groups versus no 
congestion). Neither obesity nor body mass index modified the relationship between the number 
Selvaraj S, et al. Physical Exam in HFrEF   14 
 
of signs with the primary outcome in fully adjusted models (p-interaction >0.40 for both 
comparisons). We also analyzed the association between baseline signs and adverse outcomes in 
Supplementary Table 6. This showed weaker, though significant relationships with increasing 
baseline congestion and adverse events than with the time-updated analysis. Adjustment for NT-
proBNP further attenuated, but did not eliminate, these associations. 
We performed a subanalysis of 2066 participants with complete data for NT-proBNP 
values, MAGGIC risk score, and NYHA class at 3 study visits (Supplementary Table 7). After 
adjusting for time-updated NT-proBNP and MAGGIC risk score, increasing congestion was 
generally associated with an increased risk for the primary outcome. There was further 
attenuation of the statistical significance after adjusting for time-updated NYHA class in this 
limited subanalysis.  
Supplementary Table 8 demonstrates through time-updated analysis that presence of 
each individual sign of congestion was associated with an increased risk for all events on 
univariable and multivariable analysis. Though JVD was associated with all outcomes after 
adjusting for NT-proBNP and MAGGIC risk score, it was no longer associated with the study 
endpoints after adjusting for NYHA class.  
In a complementary analysis, we assessed the prognostic value of signs using the original 
graded format in the trial protocol instead of dichotomizing rales and edema (Supplementary 
Table 9). In fully adjusted models, increasing severity of congestion was generally associated 
with a graded and increased risk for all study outcomes. We also created a congestion point score 
by weighting severity of congestion in relation to cardiovascular mortality. Each 1-point increase 
in congestion score equated to 25% increase in risk for the primary endpoint [HR 1.25, 95% 
confidence interval (CI) 1.22-1.29].  
Selvaraj S, et al. Physical Exam in HFrEF   15 
 
Since clinicians may partially base their decision to hospitalize patients on the number of 
signs of congestion, we performed a sensitivity analysis (Supplementary Table 10). Even after 
censoring those hospitalized for HF the same date as a clinic visit (N=169), there were still 
significant, strong, and graded relationships between number of signs of congestion and risk for 
the primary endpoint and HF hospitalization. The HRs for the primary endpoint for 1, 2, 3, and 4 
signs of congestion (versus 0 signs) were 1.47, 1.61, 2.05, and 3.38, respectively after 
multivariable adjustments (p<0.001 for all comparisons). 
 
Effect of sacubitril/valsartan on congestion 
Sacubitril/valsartan reduced the risk for the primary outcome regardless of the baseline 
physical exam modeled, as a continuous variable (p=0.16 for interaction). Figure 2 shows the 
percent of participants with any congestion during follow-up by treatment arm. 
Sacubitril/valsartan improved clinical congestion relative to enalapril during study follow-up 
(p=0.011).  
 
Relationship of change in physical exam to quality of life and outcomes 
We performed an analysis of participants attending the 4-month visit with available 
physical exam (N=7967). The relationship between change in the physical exam and change in 
quality of life (assessed using the KCCQ-OSS) is shown in Table 3. Each disappearance of a 
sign of congestion was associated with a 5.1 (95% CI: 4.5, 5.7) increase in KCCQ-OSS, 
indicating improvement in quality of life. Multivariable adjustment for covariates associated with 
the change in the physical examination identified in Supplementary Table 11 yielded similar 
results. Findings were similar when analyzed by each physical exam sign.  
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We subsequently sought to understand whether the risk of adverse events is mutable by 
changing congestion. Table 4 shows that change in number of signs of congestion was a strong 
predictor even after adjusting for baseline signs of congestion. For example, the HR (95% CI) for 
the primary endpoint per sign increase in congestion was 2.00 (1.89, 2.13) after adjusting for the 
number of baseline signs of congestion.  
 
DISCUSSION 
In a large study of congestion on physical examination in outpatients with HFrEF, we 
demonstrated that the number of physical examination signs of congestion was strongly 
predictive of clinical outcomes even after adjusting for baseline NT-proBNP, time-updated 
MAGGIC risk score, and time-updated NYHA class. In a subanalysis of 2066 individuals with 
complete NP data available, increasing congestion was associated with the primary outcome 
even after adjusting for time-updated NT-proBNP and MAGGIC risk score. Moreover, the effect 
of sacubitril/valsartan relative to enalapril was consistent across the baseline physical exam and 
improved congestion over enalapril. Change in the physical exam strongly related to patient-
assessed quality of life and, further, was prognostic for future events even after adjusting 
baseline physical exam. Our findings reinforce the ongoing clinical relevance of the physical 
exam in HF, reducing congestion as assessed by serial physical exams (which was independently 
associated with improved quality of life and reduced risk for adverse cardiovascular events), and 
the notion that measuring NPs does not substitute for a comprehensive exam for risk 
stratification. 
NPs have emerged as markers of volume status and prognosis in HF. Even in the absence 
of clinical congestion, the presence of elevated NPs portends a poor prognosis (a condition 
Selvaraj S, et al. Physical Exam in HFrEF   17 
 
referred to as “hemodynamic congestion”).18 PARADIGM-HF required elevated NPs as a study 
entry criterion. Thus, in our study, everyone without clinical congestion had “hemodynamic 
congestion”, with a corresponding median (25th-75th percentile) NT-pro BNP of 1529 (852, 
2969)) pg/mL. Thus, enthusiasm for NP-based algorithms to guide diuresis and HF therapy has 
recently accrued. However, the Guiding Evidence-Based Therapy Using Biomarker Intensified 
Treatment (GUIDE-IT) trial) failed to demonstrate improved clinical outcomes with such an 
approach19 and actually resulted in increased costs with similar impact on quality of life.20 Our 
results show that congestion is associated with worse outcomes even after adjusting for NPs. 
Wireless pulmonary artery hemodynamic monitoring is effective to guide decongestion and 
reduce hospitalizations, but enthusiasm for widespread implementation is tempered by cost, need 
for central monitoring capabilities, and infrequent, but potentially serious, risks related to 
implantation.21, 22 Treating HF patients based upon the physical exam, rather than biomarker 
data, is important not just to improve outcomes, but also symptoms. While intuitive, there is a 
paucity of data in chronic HF that quantifies this association. We show that each reduction in 
sign of congestion was associated with a 5-point increase in KCCQ-OSS. For perspective, a 5-
point improvement in KCCQ-OSS has been associated with a 10% reduction in cardiovascular 
mortality or hospitalization, and some have considered a 5-point increase to indicate a clinically 
significant improvement in QoL.23-25  
In PARADIGM-HF, edema was the most common sign of congestion followed by JVD. 
The frequencies observed here are largely consistent with other trials in HFrEF.6, 9, 26 
Observational studies and clinical registries of the physical exam have varied in the frequency of 
signs of congestion, which may reflect differences in patient population selected.27, 28 Inpatient 
data on the prognostic value of congestion at admission and discharge have generally been 
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concordant with our findings,29, 30 and though not frequently accomplished by discharge, relief of 
congestion has been associated with improved outcomes.31, 32 Outpatient analyses of congestion 
in HFrEF, where most clinical care occurs, are less frequent.5, 6, 9 These studies, while important, 
did not adjust for NPs and only analyzed the baseline physical exam, which may inaccurately 
quantify risk since clinical congestion can change significantly within patients over time. Indeed, 
we showed that baseline signs of congestion was a relatively weak predictor of adverse events, 
reflecting the fact that a “snapshot” of congestion at one time point does not strongly relate to 
longer term future risk, as risk appears to be mutable by change in congestion. We further 
demonstrated that time-updated change in physical exam signs during follow-up was strongly 
predictive of clinical outcomes even after adjusting for baseline signs, which therefore 
underscores the need to keep patients decongested to improve prognosis. 
 Detection of clinical congestion can be challenging, crude, and operator-dependent.29, 33, 
34 While no sign has perfect predictive value, signs of congestion in aggregate are useful to 
understanding the hemodynamic status and can inform treatment decisions. The number of signs 
was significantly more predictive than using any individual sign (or models just assessing 1+ 
signs versus 0 signs), which emphasizes the importance of a thorough physical exam. Further, 
the physical exam may be challenging in obese individuals, a population also in whom NP levels 
may be “leftward shifted”. However, we found no effect modification by obesity or body mass 
index on the predictive value of clinical congestion.  
Sacubitril/valsartan reduced the number of signs of congestion over time compared with 
enalapril. The modest observed improvement in congestion may be related to 1) greater increase 
in diuretic use in the enalapril arm over time;35 2) survivorship bias, whereby the sickest patient 
may not have presented later in follow-up, as more deaths occurred in the enalapril arm; 3) 
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assessment of congestive signs at randomization, which occurred after sequential run-in phases 
with enalapril and sacubitril/valsartan that may have attenuated differences between arms.  
Strengths of our study include the large sample size, population receiving contemporary 
HF management, time-updated analysis of the physical exam with numerous follow-up visits, 
assessment of quality of life using a validated instrument, and event adjudication. In addition, we 
adjusted for several strong predictors of prognosis, such as NT-proBNP, MAGGIC risk score, 
and NYHA class.  
 
Limitations 
Our analysis has some possible limitations. Performance of the physical exam by the 
study investigators was not standardized. In addition, signs may have considerable interobserver 
variability, and confirmatory methods were not employed. However, our analysis is reflective of 
clinical practice and therefore increases generalizability of our findings. Next, signs of 
congestion may influence a physician’s decision to hospitalize patients and therefore might 
explain the relationship between the physical exam and HF hospitalization. However, our results 
were relatively similar in a sensitivity analysis censoring patients who were hospitalized the 
same date as a clinic visit. In addition, signs of congestion powerfully predicted other outcomes 
that would be unaffected by a physician’s knowledge of the physical exam, including 
cardiovascular death and all-cause mortality.  Finally, historical features might influence a 
clinician’s evaluation of the physical examination. However, our results were robust even after 
adjusting for symptoms as reflected by NYHA class.  
In summary, in the largest study to date of the physical exam in HF, signs of congestion 
independently predicted adverse events even after adjusting for NPs, MAGGIC risk score, and 
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NYHA class. Improvement in the physical exam was associated with improved quality of life 
and prognosis. The effect of sacubitril/valsartan relative to enalapril was consistent across the 
baseline physical exam, and sacubitril/valsartan improved congestion over enalapril. The 
physical exam, a highly utilized and readily available assessment in HF, continues to have strong 
utility in the contemporary era of HFrEF treatment. 
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FIGURE LEGENDS 
Figure 1:  
Title: Time-Updated Event Rates for Efficacy Outcomes by Total Number of Signs of 
Congestion. 
Caption: Event rates using time-updated analysis per 100 person-years and 95% confidence 
intervals are shown for each of the four efficacy outcomes by treatment arm (enalapril shown in 
blue, sacubitril/valsartan shown in red). Participants can contribute person-years to more than 
one category as they increase or decrease in the number of signs of congestion during their 
clinical trajectory. The number of events and person-years in each sign category is presented in 
Supplementary Table 5. CV, cardiovascular; HF, heart failure. 
 
Figure 2: 
Title: Percent of Patients with Any Congestion During Follow-up by Randomization Arm. 
Caption: Sacubitril/valsartan (red) reduced the frequency of patients with any congestion 
relative to enalapril (blue) during follow-up. Error bars denote 95% confidence intervals. The 
number of participants at each study visit by randomization arm is shown in the bottom table. P-
value shown for binary repeated measures logistic regression.  
 
 
 
 
Selvaraj S, et al. Physical Exam in HFrEF   26 
 
TABLE 1. Baseline Clinical Characteristics by Number of Physical Exam Signs 
 0 Signs 
N=5854 
1 Sign 
N=1783 
2 Signs 
N=563 
3-4 Signs 
N=180 
P-value* 
Jugular venous distention - 378     (21.2%) 269     (47.8%) 170     (94.4%) <0.001 
Edema - 675     (37.9%) 366     (65.0%) 152     (84.4%) <0.001 
S3 heart sound - 475     (26.6%) 217     (38.5%) 104     (57.8%) <0.001 
Rales - 255     (14.3%) 274     (48.7%) 134     (74.4%) <0.001 
Age, years 63   ± 11 64   ± 12 66   ± 11 65   ± 10 <    0.001 
Female, n (%) 1219    (20.8%) 436     (24.5%) 124     (22.0%) 52      (28.9%) 0.001 
Race, n (%)     0.042 
    White 3856    (65.9%) 1131    (63.4%) 
411     
(73.0%) 
135     
(75.0%)  
    Black 303     (5.2 %) 86      (4.8 %) 25      (4.4 %) 11      (6.1 %)  
    Asian 1085    (18.5%) 343     (19.2%) 66      (11.7%) 11      (6.1 %)  
    Other 610     (10.4%) 223     (12.5%) 61      (10.8%) 23      (12.8%)  
 Region     <0.001 
    North America 438     (7.5 %) 124     (7.0 %) 31      (5.5 %) 7       (3.9 %)  
    Latin American 1016    (17.4%) 298     (16.7%) 94      (16.7%) 22      (12.2%)  
    Western Europe  1582    (27.0%) 375     (21.0%) 70      (12.4%) 18      (10.0%)  
    Central Europe 1757    (30.0%) 640     (35.9%) 303     (53.8%) 
123     
(68.3%)  
    Asia-Pacific 1061    (18.1%) 346     (19.4%) 65      (11.5%) 10      (5.6 %)  
NYHA Class, n (%)     <0.001 
    I 315     (5.4 %) 68      (3.8 %) 6       (1.1 %) 0       (0.0 %)  
    II 4515    (77.1%) 1090    (61.1%) 
253     
(44.9%) 55      (30.6%)  
    III 1007    (17.2%) 610     (34.2%) 286     (50.8%) 
115     
(63.9%)  
    IV 17      (0.3 %) 15      (0.8 %) 18      (3.2 %) 10      (5.6 %)  
Diagnosis of heart failure     0.21 
    <1 year 1782    (30.4%) 543     (30.5%) 144     48      (26.7%)  
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(25.6%) 
    1-5 years 2230    (38.1%) 680     (38.1%) 235     (41.7%) 78      (43.3%)  
    >5 years 1842    (31.5%) 560     (31.4%) 184     (32.7%) 54      (30.0%)  
MAGGIC risk score 20.3 ± 5.6 21.5 ± 5.8 22.6 ± 5.8 22.2 ± 6.2 <    0.001 
Kansas City 
Cardiomyopathy 
Questionnaire overall score 
76   ± 18 69   ± 20 62   ± 21 57   ± 21 <    0.001 
Physical Characteristics      
   Systolic blood pressure, 
mmHg 121  ± 15 122  ± 15 124  ± 14 127  ± 15 <    0.001 
   Diastolic blood pressure, 
mmHg 73   ± 10 74   ± 10 76   ± 9 78   ± 10 <    0.001 
     Heart rate (beats/min) 72   ± 12 73   ± 12 75   ± 13 78   ± 14 <    0.001 
     Body mass index (kg/m2)  28.0 ± 5.4 28.6 ± 6.0 28.4 ± 5.7 29.3 ± 5.2 <    0.001 
Comorbidities, n (%)      
     Hypertension 4067    (69.5%) 1285    (72.1%) 
425     
(75.5%) 
152     
(84.4%) <0.001 
     Atrial fibrillation 2044    (34.9%) 700     (39.3%) 264     (46.9%) 75      (41.7%) <0.001 
     Diabetes mellitus 1961    (33.5%) 662     (37.1%) 207     (36.8%) 72      (40.0%) 0.002 
     Ischemic heart disease 3507    (59.9%) 1065    (59.7%) 
342     
(60.7%) 
108     
(60.0%) 0.85 
     Myocardial infarction 2538    (43.4%) 771     (43.2%) 244     (43.3%) 71      (39.4%) 0.54 
     Heart failure 
hospitalization 3627    (62.0%) 
1121    
(62.9%) 
392     
(69.6%) 
123     
(68.3%) <0.001 
     Stroke 520     (8.9 %) 141     (7.9 %) 53      (9.4 %) 10      (5.6 %) 0.25 
     Current smoker 875     (14.9%) 248     (13.9%) 59      (10.5%) 23      (12.8%) 0.008 
Medication and Device 
Use, n (%)      
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     Beta-blocker 5480    (93.6%) 1630    (91.4%) 
519     
(92.2%) 
165     
(91.7%) 0.007 
     Digitalis 1679    (28.7%) 603     (33.8%) 201     (35.7%) 54      (30.0%) <0.001 
     Diuretic 4530    (77.4%) 1526    (85.6%) 
503     
(89.3%) 
167     
(92.8%) <0.001 
     Mineralocorticoid 
antagonist 3243     (55.4%) 998     (56.0%) 
327     
(58.1%) 93      (51.7%) 0.70 
     Implantable cardioverter-
defibrillator 940     (16.1%) 233     (13.1%) 58      (10.3%) 10      (5.6 %) <0.001 
    Cardiac resynchronization 
therapy 426     (7.3 %) 109     (6.1 %) 33      (5.9 %) 5       (2.8 %) 0.005 
Laboratory Testing      
     Estimated glomerular 
filtration rate (mL/min/1.78 
m2) 
68.0 ± 19.9 66.8 ± 20.8 67.2 ± 19.9 70.1 ± 21.3 0.47 
     Hemoglobin (mg/dL) 14.0  ± 1.6 13.8  ± 1.7 13.9  ± 1.7 14.1  ± 1.8 0.006 
     BNP (pg/mL) † 242  [149, 442 ] 274  [163, 523 ] 
297  [176, 587 
] 
363  [185, 710 
] <0.001 
     NT-pro-BNP (pg/mL) † 1529 [852, 
2969] 
1785 [978, 
3785] 
1909 [1020, 
4138] 
2181 [1156, 
5538] <0.001 
Imaging Data      
     Ejection fraction (%) 29.5 ± 6.2 29.3 ± 6.2 29.7 ± 6.1 30.1 ± 6.1 0.51 
NYHA, New York Heart Association; BNP, b-type natriuretic peptide. 
*P-value shown for trend. 
†Presented as median (25th – 75th percentile) since the variable is right-skewed.  
  
Selvaraj S, et al. Physical Exam in HFrEF   29 
 
TABLE 2. Crude and Adjusted Hazard Ratios using Time-updated Signs of Congestion for Efficacy Outcomes by Total 
Number of Physical Exam Signs 
Outcomes 1 Sign vs. 0 Signs 
HR (95% CI) 
2 Signs vs. 0 Signs 
HR (95% CI) 
3 Signs vs. 0 Signs 
HR (95% CI) 
4 Signs vs. 0 Signs 
HR (95% CI) 
Composite endpoint     
● Crude model  1.77 (1.59, 1.96) 2.61 (2.24, 3.03) 4.22 (3.45, 5.16) 11.88 (8.17, 17.29) 
● Adjustment for baseline NT-
proBNP 
1.68 (2.03, 2.74) 2.36 (2.03, 2.74) 3.60 (2.94, 4.40) 10.53 (7.24, 15.33) 
● Adjustment for baseline NT-
proBNP and time-updated 
MAGGIC score  
1.62 (1.46, 1.80) 2.20 (1.89, 2.55) 3.43 (2.80, 4.20) 9.03 (6.20, 13.16) 
● Adjustment for baseline NT-
proBNP, time-updated 
MAGGIC score, and time-
updated NYHA class 
1.48 (1.34, 1.65) 1.74 (1.49, 2.03) 2.35 (1.90, 2.90) 5.96 (4.06, 8.74) 
Cardiovascular mortality     
● Crude model  1.76 (1.54, 2.01) 2.89 (2.41, 3.45) 3.82 (2.95, 4.93) 7.45 (4.46, 12.42) 
● Adjustment for baseline NT-
proBNP 
1.65 (1.45, 1.89) 2.56 (2.14, 3.06) 3.16 (2.44, 4.08) 5.62 (3.36, 9.39) 
● Adjustment for baseline NT-
proBNP and time-updated 
MAGGIC score  
1.57 (1.38, 1.80) 2.33 (1.95, 2.79) 2.95 (2.28, 3.82) 4.71 (2.82, 7.88_ 
● Adjustment for baseline NT-
proBNP, time-updated 
MAGGIC score, and time-
updated NYHA class 
1.43 (1.25, 1.64) 1.82 (1.51, 2.20) 1.99 (1.52, 2.61) 2.60 (1.53, 4.42) 
Heart failure hospitalization     
● Crude model  2.00 (1.75, 2.29) 2.89 (2.38, 3.51) 5.84 (4.61, 7.39) 18.99 (12.73, 28.33) 
● Adjustment for baseline NT- 1.91 (1.67, 2.18) 2.64 (2.17, 3.20) 5.03 (3.97, 6.37) 17.04 (11.42, 25.44) 
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proBNP 
● Adjustment for baseline NT-
proBNP and time-updated 
MAGGIC score  
1.84 (1.61, 2.10) 2.45 (2.02, 2.98) 4.79 (3.78, 6.07) 14.55 (21.76) 
● Adjustment for baseline NT-
proBNP, time-updated 
MAGGIC score, and time-
updated NYHA class 
1.64 (1.43, 1.88) 1.84 (1.50, 2.25) 3.00 (2.34, 3.86) 8.82 (5.84, 13.31) 
All cause mortality     
● Crude model  1.61 (1.43, 1.82) 2.76 (2.35, 3.24) 3.50 (2.76, 4.42) 6.63 (4.10, 10.72) 
● Adjustment for baseline NT-
proBNP 
1.52 (1.35, 1.72) 2.47 (2.10, 2.91) 2.95 (2.33, 3.74) 5.16 (3.19, 8.35) 
● Adjustment for baseline NT-
proBNP and time-updated 
MAGGIC score  
1.44 (1.28, 1.63) 2.23 (1.90, 2.63) 2.75 (2.17, 3.48) 4.27 (2.64, 6.92) 
● Adjustment for baseline NT-
proBNP, time-updated 
MAGGIC score, and time-
updated NYHA class 
1.32 (1.17, 1.49) 1.78 (1.51, 2.12) 1.92 (1.50, 2.47) 2.53 (1.54, 4.15) 
HR, hazard ratio; CI, confidence interval; NT-proBNP, N-terminal pro-B-type natriuretic peptide; MAGGIC, Meta-Analysis Global Group in Chronic Heart 
Failure; NYHA, New York Heart Association 
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TABLE 3. Relationship between Reducing Signs of Congestion and Quality of Life from Baseline to the 4-Month Visit. 
 
 Change in KCCQ-OSS per 
Reduction in Sign of 
Congestion 
Minimally-adjusted Model 
Beta-coefficient (95% CI)* 
P-value Change in KCCQ-OSS per 
Reduction in Sign of 
Congestion 
Fully-adjusted Model 
Beta-coefficient (95% CI)* † 
P-value 
Change per decrease in 
number of physical exam signs 
5.1 (4.5, 5.7) <0.001 4.9 (4.3, 5.5) <0.001 
Edema 7.8 (6.7, 8.9) <0.001 7.4 (6.3, 8.5) <0.001 
S3 3.2 (1.5, 5.0) <0.001 3.0 (1.3, 4.8) 0.001 
Jugular venous distention 7.3 (5.8, 8.7) <0.001 6.9 (5.5, 8.4) <0.001 
Rales 7.0 (5.5, 8.4) <0.001 6.7 (5.3, 8.1) <0.001 
CI, confidence interval; KCCQ-OSS, Kansas City Cardiomyopathy Questionnaire Overall Summary Score. 
*Expressed per decrease in, or absence of, physical exam sign. All analyses controlled for randomization arm and baseline physical 
exam.  
†Additionally adjusted for enrollment from Latin America, diabetes mellitus, enrollment from Western Europe, body mass index, log 
NT-proBNP, and diuretic use.  
  
Selvaraj S, et al. Physical Exam in HFrEF   32 
 
TABLE 4. Prognostic Value of Baseline Signs and Change in Signs 
Outcomes Baseline Number 
of Signs 
HR (95% CI)* 
P-value Change in Number of 
Signs 
HR (95% CI) †‡ 
P-value 
Composite endpoint 1.47 (1.39, 1.55) <0.001 2.00 (1.89, 2.13) <0.001 
Cardiovascular mortality 1.45 (1.35, 1.56) <0.001 1.85 (1.72, 1.99) <0.001 
HF hospitalization 1.50 (1.40, 1.61) <0.001 2.31 (2.15, 2.49) <0.001 
All cause mortality 1.42 (1.33, 1.51) <0.001 1.78 (1.66, 1.90) <0.001 
HF, heart failure; CI, confidence interval. 
*Adjusted for change in number of signs 
†Adjusted for baseline number of signs 
‡Change in number of signs is time-updated at each visit from baseline signs 
 
 
